Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin.

Tai-Jan ChiuShih-Hung YangSz-Chi ChiuShun-Wen HsuehNai-Jung ChiangChung-Pin LiLi-Yuan BaiFu-Ming ChengShih-Chang ChuangYan-Shen ShanDe-Chuan ChanLi-Tzong ChenChia-Jui YenCheng-Ming PengYung-Yeh SuYen-Yang ChenJen-Shi ChenWen-Chi Chou

Published in: Journal of hepato-biliary-pancreatic sciences (2022)

Previous conventional irinotecan treatment does not compromise the efficacy of subsequent nal-IRI+5-FU/LV treatment in mPDAC patients.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
combination therapy
patient reported outcomes